Background/Objectives:Red blood cell transfusions for anemia impose high financial and healthcare resource utilization burdens on patients with myelofibrosis (MF). This study estimates projected differences in medical costs and transfusion-related cost and time burdens with momelotinib vs. ruxolitinib or best available therapy (BAT) in Janus kinase (JAK) inhibitor–naive and –experienced patients.Methods:Analyses used 24-week transfusion data from the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials and cost estimates from a study of adult patients with MF using the US IBM MarketScan Commercial database. The analyses were stratified by transfusion status at baseline (transfusion dependent [TD], transfusion independent/requiring [TI/TR]). Subgroup analyses were conducted among patients with anemia (moderate anemia, hemoglobin ≥ 8 to <10 g/dL; moderate-to-severe anemia, hemoglobin < 10 g/dL) and for patients aged ≥65 years. Cost estimates for patients aged ≥65 years were extracted from a study using the Medicare Fee-for-Service database.Results:In JAK inhibitor-naive patients, momelotinib was projected to result in cost and time savings vs. ruxolitinib in both TD and TI/TR patients across all populations evaluated. Projected cost and time savings were also observed with momelotinib vs. BAT in JAK inhibitor-experienced patients across all populations evaluated, primarily in TD patients.Conclusions:These results suggest that momelotinib may provide medical and transfusion-related cost and time burden offsets for both JAK inhibitor-naive and -experienced patients with MF.
背景/目的：针对骨髓纤维化（MF）患者的贫血进行红细胞输注，给患者带来了高昂的经济和医疗资源负担。本研究旨在评估在未使用过或已使用过Janus激酶（JAK）抑制剂的患者中，使用莫莫洛替尼相较于鲁索替尼或最佳可用疗法（BAT）在医疗成本及输血相关成本与时间负担方面的预期差异。 方法：分析基于第三阶段SIMPLIFY-1和SIMPLIFY-2试验的24周输血数据，以及使用美国IBM MarketScan商业数据库对成年MF患者进行的成本估算。分析根据基线输血状态（输血依赖型[TD]、输血非依赖型/需要输血型[TI/TR]）进行分层。针对贫血患者（中度贫血，血红蛋白≥8至<10 g/dL；中重度贫血，血红蛋白<10 g/dL）以及年龄≥65岁的患者进行了亚组分析。年龄≥65岁患者的成本估算数据来源于一项使用Medicare按服务付费数据库的研究。 结果：在未使用过JAK抑制剂的患者中，莫莫洛替尼预计在所有评估人群中，无论是TD还是TI/TR患者，相较于鲁索替尼均能节省成本和时间。在已使用过JAK抑制剂的患者中，莫莫洛替尼相较于BAT在所有评估人群中（主要在TD患者中）也显示出预期的成本和时间节省。 结论：这些结果表明，莫莫洛替尼可能为未使用过或已使用过JAK抑制剂的MF患者提供医疗及输血相关成本与时间负担的补偿。
肿瘤(癌症)患者之家